Skip to main content

PsA/SpA

FDA Approves Taltz for Non-Radiographic Axial Spondyloarthritis

Jun 01, 2020

Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Ixekizumab (an IL-17A inhibitor) would join certolizumab (TNF inhibitor) as the only 2 drugs approved by the FDA for nr-

Read Article

First Look at COVID-19 Global Rheumatology Alliance Registry

Jun 01, 2020

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect

Read Article

Boston and Wuhan Report Rheum COVID Patients at Risk for Respiratory Failure

May 27, 2020

Two current reports from Boston and Wuhan describe cohorts of COVID-19 (+) rheumatic disease patients who generally do well but appear to have a higher risk of pulmonary involvement.

Read Article

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

May 25, 2020

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Read Article
A patient service Video - How to Manage your Arthritis Medications (in the time of COVID) - View the video here: https://t.co/hWW0h8wCZn or listen to the podcast on iTunes or here>> https://t.co/8wV4V2pYY5
Dr. John Cush RheumNow ( View Tweet)
May 21, 2020

TNR - COVID-Rheumatology Registry & COVID in OZ

May 19, 2020

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in

Read Article
Study of 274 women with axSpA shows that longer time to pregnancy (TTP) was associated with older age, nulliparity, and longer disease duration. https://t.co/GznVvnPAwO

Dr. John Cush RheumNow ( View Tweet)

May 12, 2020

Secukinumab Better than Adalimumab - Maybe?

May 11, 2020

The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher

Read Article
The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv

Dr. John Cush RheumNow ( View Tweet)

May 10, 2020

RheumNow Podcast – The Beat Goes On (5.8.20)

May 07, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Italian study of 1193 Psoriasis pts, there were 17 biologic (TNF, UST, IL17 IL23) treated COVID cases. When compared to 19 local nonPSO/Nonbiologic pts.

Dr. John Cush RheumNow ( View Tweet)

May 07, 2020

TNR Grand Rounds: IL-6 in Health and Disease

May 06, 2020

Dr. Len Calabrese from the Cleveland Clinic delivers this week's Tuesday Nite Rheumatology Grand Rounds, entitled "IL-6 in Health and Disease: Where Rheumatology Meets COVID-19".

Dr. Calabrese provides a comprehensive review of IL-6 biology, and discusses IL-6 signaling, IL-6 roles in health,

Read Article
European Commission has approved Cosentyx (secukinumab) for Rx of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) based on results of the Phase III PREVENT trial. (NOT yet FDA/US approved for nr-axSpA) https://t.co/DAWWoG6MJP

Dr. John Cush RheumNow ( View Tweet)

May 06, 2020

Hydroxychloroquine's World of Confusion - What you Need to Know

May 05, 2020

Hydroxychloroquine has been a dominant news item since the start of the COVID-19 crisis, with a great deal of misconceptions by those who don't know or use or take the drug. HCQ leaped to the headlines on March 19th when President Trump endorsed the drug as being “approved” by FDA. Of course at

Read Article

ACR: In-Person Urgent vs. Virtual Non-Urgent Medical Care

May 05, 2020

On April 26, 2020 the American College of Rheumatology (ACR) published a guidance paper to assist rheumatologists and rheumatology health professionals in assessing the need for urgent or face-to-face medical care versus virtual or telehealth patient care.  The driving principals being the

Read Article

Hydroxychloroquine and QTc Prolongation

May 04, 2020

JAMA Cardiology reports the risk of QT (QTc) prolongation when hydroxychloroquine (HCQ) was given to hospitalized patients with coronavirus disease 2019 (COVID-19), especially when given with azithromycin. 

This single center, cohort study included 90 hospitalized patients with

Read Article
RA & SpA in remission - if you taper biologic or JAK, what happens to infection risk = Nothing! Metanalysis of 13 studies 2260 pts in remission finds no diff in serious infx rate in taper group(1.7/100PY) vs usual care(2.6/100PY)(p=0.13); no diff in SAE!

Dr. John Cush RheumNow ( View Tweet)

Apr 30, 2020
NYC, NYU COVID infected Rheum pts (n 86 RA, PsA, AS, PsO, IBD); 16% Hospitalized.
Dr. John Cush RheumNow ( View Tweet)
Apr 30, 2020
ACR has published COVID-19 Recs -American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic by Mikuls Johnson Fraenkel Arasaratnam Baden Bermas Chatham https://t.co/wwpslcLXx2

Dr. John Cush RheumNow ( View Tweet)

Apr 30, 2020

German Society of Rheumatology COVID Pandemic Recommendations

Apr 30, 2020

The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.

These preliminary recommendations are based on an expert consensus from 17

Read Article

IL-6 Inhibitors May Benefit COVID-19 Infection

Apr 28, 2020

In the last few days there have been encouraging "preliminary" reports that IL-6 inhibition by either tocilizumab or sarilumab may be efficacious in patients with severe coronavirus infections.

Read Article
French retrospective study of 429 pts (302 SpA, 127 PsA) compared 203 on TNF inhib mAb vs 226 on etandercept as 1st TNFi.
Dr. John Cush RheumNow ( View Tweet)
Apr 28, 2020

High Dose Chloroquine Harmful in Severe COVID-19

Apr 27, 2020

JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.

Read Article
ACR Guidance for Rheumatic Disease during COVID-19 pandemic #Rheumatology @RheumNow https://t.co/vHav6g4p6Q
Maeve Gamble MaeveGamble ( View Tweet)
Apr 24, 2020
NICE guidelines on managing rheumatologic conditions during COVID-19 #Rheumatology @RheumNow https://t.co/dQcavsno5N
Maeve Gamble MaeveGamble ( View Tweet)
Apr 24, 2020
×